Latest Communications

19 March 2012
Nautlius Neurosciences, Inc. Announces a New Approval for CAMBIA® in the Acute Treatment of Migraine

01 March 2012
APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the European approval of Zolmitriptan Oral Dispersible Film (ODF)

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.


Think Tank


For all those companies and Inventors who own innovative projects for which they wish to maintain an active role in exploiting them but do not have either development and marketing Know How or the required financial resources, we have created a great place where such projects can be shaped: we call it "Think Tank".


In the Think Tank area, APR is acting as a mix of strategic and financial investor able to provide a balanced mix of capital funding and development Know How channeled into a new company created ad hoc for that specific project and where the inventor can maintain an equity position enabling him to secure the upside potential.


We welcome your ideas and we will carefully listen to them: we will openly and professionally evaluate them all.





Search results